Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
Applications for subcutaneous daratumumab as monotherapy for high-risk smoldering multiple myeloma have been submitted to the FDA and EMA, supported by data from the phase 3 AQUILA trial. Initial findings will be presented at the 2024 ASH Annual Meeting. Daratumumab could become the first approved treatment for this patient group, potentially altering the treatment paradigm.
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CervoMed Inc. wins Prix Galien USA 2024 Best Startup award for developing potential treatment for Dementia with Lewy bodies (DLB), a condition affecting over 1.4 million patients in the U.S. and EU. The company's drug, neflamapimod, is in Phase 2b clinical trial, with topline results expected in December 2024.
Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma
Johnson & Johnson submits regulatory applications for Darzalex Faspro to the FDA and Darzalex to the EMA, based on Phase 3 AQUILA study data for high-risk smoldering multiple myeloma. If approved, Darzalex Faspro would be the first treatment option for this condition.
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cidara Therapeutics reports Q3 2024 financials, highlights Phase 2b NAVIGATE trial for CD388 influenza prophylaxis, restructuring to focus on CD388 development, and presentations at 2024 IDWeek and OPTIONS XII conferences. Cash and equivalents total $127.4 million, with net loss of $16.0 million for Q3 2024.
FDA approves J&J's device for heart condition
FDA approves Johnson & Johnson's Varipulse, a pulsed field ablation system for treating abnormal heart rhythm.
Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX
Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO and DARZALEX SC, targeting high-risk smoldering multiple myeloma. AQUILA study (NCT03301220) investigates DARZALEX FASPRO versus active monitoring in 390 patients, focusing on progression-free survival. Smoldering multiple myeloma, an asymptomatic precursor to multiple myeloma, affects 15% of newly diagnosed cases, with half of high-risk patients progressing within two years. Multiple myeloma, a blood cancer affecting plasma cells, is the second most common blood cancer globally, with an estimated 35,000 new cases and 12,000 deaths in the U.S. in 2024.
Johnson & Johnson seeks FDA, EMA nod for myeloma treatment
Johnson & Johnson has submitted applications to the FDA and EMA for DARZALEX FASPRO® to treat high-risk smoldering multiple myeloma, based on Phase 3 AQUILA study data. If approved, it would be the first therapy for this patient population before full-blown disease onset. DARZALEX FASPRO® is currently approved for multiple myeloma indications and is the only subcutaneous CD38-directed antibody treatment. Johnson & Johnson also reported strong Q3 results and raised its full-year guidance, with analyst upgrades following robust sales. The company faces ongoing legal challenges, including a recent $15 million talc cancer case verdict.
Johnson & Johnson submits applications in the U.S. and EU
Janssen-Cilag International NV submits regulatory applications to the FDA and EMA for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and DARZALEX (daratumumab) SC for high-risk smouldering multiple myeloma, supported by Phase 3 AQUILA study data. Daratumumab could become the first treatment for this condition, potentially shifting the treatment paradigm.
Johnson & Johnson submits applications in the U.S. and EU seeking approval of ...
Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO® as a treatment for high-risk smoldering multiple myeloma, supported by Phase 3 AQUILA study data.
After decades, FDA finally moves to pull ineffective decongestant off shelves
The FDA proposed removing oral phenylephrine from OTC products due to its ineffectiveness as a nasal decongestant, based on multiple studies showing no significant difference from placebo. The proposal follows years of reevaluation since its 1976 approval.
© Copyright 2024. All Rights Reserved by MedPath